Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1012 participants.
Also called NCT01176968
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,012 participants
- Registry
-
NCT01176968 -
2010-019844-38
-
- Other papers using this trial's data
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada, Czechia, France, Germany, Greece, Hungary, Netherlands, Poland, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01176968. Randomized; quadruple masking; primary purpose prevention. Start 2010-09 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2016-08-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
- Acronym
- REMINDER
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Eplerenone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Record details
- Record id
cardio:ct-nct01176968- Content hash
a18837bc7b4e16084544f0534a830b64498dd50393b41fc2b22b99f78bc074e9